Drug Nanoparticle Formulation Using Ascorbic Acid Derivatives

Figure 2

Comparison of solubilization and nanoparticle formation characteristics between the CAM-ascorbic acid (ASA) and CAM-ASC-G systems. (A) Particle fractions of the drug in the CAM : ASC-G systems. (B) Changes in the mean particle size of CAM fine particles after storage: (a) Unprocessed CAM, (b) PM (CAM : ASC-G = 2 : 1), (c) GM (CAM : ASC-G = 2 : 1), (d) PM (CAM : ASA = 2 : 1), and (e) GM (CAM : ASA = 2 : 1).